2023 was a tough year for the biopharma industry, with several companies downsizing and restructuring their workforces to stay afloat. There are signs of recovery, as mergers and acquisitions picked up across the pharmaceutical and life sciences industry in the latter part of 2023 and have continued their upswing into 2024. Will the job market follow suit?
BioSpace will continue to be your source of news on job cuts and restructuring initiatives throughout 2024. Follow along as we keep you up to date on which companies are tightening their belts and cutting staff.
April
April 4
As a result of its decision to pull ALS drug Relyvrio from the U.S. and Canadian markets following a Phase III trial failure, Amylyx Pharmaceuticals will downsize its workforce by about 70%. The company disclosed in a regulatory filing that it had 384 employees…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Governor, business groups, trial lawyers reach compromise to avoid ballot war over lawsuit damages
With four days left in the legislative session, business groups, the governor’s office, legislative leadership and trial lawyers announced a compromise they say could avoid bitter battles at the ballot box seeking to alter or […]
Fast-growing Denver healthtech unicorn lays off nearly 50 employees
Another round of layoffs is impacting Denver-area employees. SonderMind, a fast-growing healthtech company based in Denver, recently laid off 17% of its workforce, or 49 employees, the company confirmed with the Denver Business Journal on […]
Does TikTok-Fueled Vagus Nerve Icing Offer Calming Relief?
A young woman’s TikTok video claiming that icing her chest with a bag of frozen peas conquered her until-then untouchable insomnia must have hit a nerve. Click here to view original post
